122 related articles for article (PubMed ID: 12766905)
1. Mutation analysis of CDP, TP53, and KRAS in uterine leiomyomas.
Patrikis MI; Bryan EJ; Thomas NA; Rice GE; Quinn MA; Baker MS; Campbell IG
Mol Carcinog; 2003 Jun; 37(2):61-4. PubMed ID: 12766905
[TBL] [Abstract][Full Text] [Related]
2. p53 alterations in uterine leiomyosarcomas versus leiomyomas.
de Vos S; Wilczynski SP; Fleischhacker M; Koeffler P
Gynecol Oncol; 1994 Aug; 54(2):205-8. PubMed ID: 8063247
[TBL] [Abstract][Full Text] [Related]
3. Loss of heterozygosity and reduced expression of the CUTL1 gene in uterine leiomyomas.
Zeng WR; Scherer SW; Koutsilieris M; Huizenga JJ; Filteau F; Tsui LC; Nepveu A
Oncogene; 1997 May; 14(19):2355-65. PubMed ID: 9178912
[TBL] [Abstract][Full Text] [Related]
4. Aberrant expression of HMGA2 in uterine leiomyoma associated with loss of TSC2 tumor suppressor gene function.
Hunter DS; Klotzbücher M; Kugoh H; Cai SL; Mullen JP; Manfioletti G; Fuhrman U; Walker CL
Cancer Res; 2002 Jul; 62(13):3766-72. PubMed ID: 12097287
[TBL] [Abstract][Full Text] [Related]
5. Expression of N-terminally truncated isoforms of CDP/CUX is increased in human uterine leiomyomas.
Moon NS; Rong Zeng W; Premdas P; Santaguida M; Bérubé G; Nepveu A
Int J Cancer; 2002 Aug; 100(4):429-32. PubMed ID: 12115525
[TBL] [Abstract][Full Text] [Related]
6. Biallelic inactivation of fumarate hydratase (FH) occurs in nonsyndromic uterine leiomyomas but is rare in other tumors.
Lehtonen R; Kiuru M; Vanharanta S; Sjöberg J; Aaltonen LM; Aittomäki K; Arola J; Butzow R; Eng C; Husgafvel-Pursiainen K; Isola J; Järvinen H; Koivisto P; Mecklin JP; Peltomäki P; Salovaara R; Wasenius VM; Karhu A; Launonen V; Nupponen NN; Aaltonen LA
Am J Pathol; 2004 Jan; 164(1):17-22. PubMed ID: 14695314
[TBL] [Abstract][Full Text] [Related]
7. Polymorphism of the p53 tumor suppressor gene is associated with susceptibility to uterine leiomyoma.
Denschlag D; Bettendorf H; Watermann D; Keck C; Tempfer C; Pietrowski D
Fertil Steril; 2005 Jul; 84(1):162-6. PubMed ID: 16009172
[TBL] [Abstract][Full Text] [Related]
8. Mutational analysis of MED12 exon 2 in uterine leiomyoma and other common tumors.
Je EM; Kim MR; Min KO; Yoo NJ; Lee SH
Int J Cancer; 2012 Sep; 131(6):E1044-7. PubMed ID: 22532225
[TBL] [Abstract][Full Text] [Related]
9. Microallelotyping defines novel regions of loss of heterozygosity in uterine leiomyomas.
Canevari Rde A; Pontes A; Rogatto SR
Mol Carcinog; 2005 Mar; 42(3):177-82. PubMed ID: 15605361
[TBL] [Abstract][Full Text] [Related]
10. Germline and somatic NF1 gene mutation spectrum in NF1-associated malignant peripheral nerve sheath tumors (MPNSTs).
Upadhyaya M; Kluwe L; Spurlock G; Monem B; Majounie E; Mantripragada K; Ruggieri M; Chuzhanova N; Evans DG; Ferner R; Thomas N; Guha A; Mautner V
Hum Mutat; 2008 Jan; 29(1):74-82. PubMed ID: 17960768
[TBL] [Abstract][Full Text] [Related]
11. [TP53 mutations and molecular epidemiology].
Otsuka K; Ishioka C
Gan To Kagaku Ryoho; 2007 May; 34(5):683-9. PubMed ID: 17496437
[TBL] [Abstract][Full Text] [Related]
12. Genomic instability, mutations and expression analysis of the tumour suppressor genes p14(ARF), p15(INK4b), p16(INK4a) and p53 in actinic keratosis.
Kanellou P; Zaravinos A; Zioga M; Stratigos A; Baritaki S; Soufla G; Zoras O; Spandidos DA
Cancer Lett; 2008 Jun; 264(1):145-61. PubMed ID: 18331779
[TBL] [Abstract][Full Text] [Related]
13. TP53 mutations and S-phase fraction but not DNA-ploidy are independent prognostic indicators in laryngeal squamous cell carcinoma.
Russo A; Corsale S; Agnese V; Macaluso M; Cascio S; Bruno L; Surmacz E; Dardanoni G; Valerio MR; Vieni S; Restivo S; Fulfaro F; Tomasino RM; Gebbia N; Bazan V
J Cell Physiol; 2006 Jan; 206(1):181-8. PubMed ID: 15965904
[TBL] [Abstract][Full Text] [Related]
14. Mutations in the p53 and Ki-ras genes, microsatellite instability and site of tumor origin in colorectal cancer.
Catalano T; Curia MC; Aceto G; Verginelli F; Cascinu S; Cama A; Mariani-Costantini R; Teti D; Battista P
Oncol Rep; 2005 Sep; 14(3):625-31. PubMed ID: 16077965
[TBL] [Abstract][Full Text] [Related]
15. Analysis of Ki-ras, p53, and MDM2 genes in uterine leiomyomas and leiomyosarcomas.
Hall KL; Teneriello MG; Taylor RR; Lemon S; Ebina M; Linnoila RI; Norris JH; Park RC; Birrer MJ
Gynecol Oncol; 1997 May; 65(2):330-5. PubMed ID: 9159347
[TBL] [Abstract][Full Text] [Related]
16. High sensitivity scanning of colorectal tumors and matched plasma DNA for mutations in APC, TP53, K-RAS, and BRAF genes with a novel DHPLC fluorescence detection platform.
Lilleberg SL; Durocher J; Sanders C; Walters K; Culver K
Ann N Y Acad Sci; 2004 Jun; 1022():250-6. PubMed ID: 15251969
[TBL] [Abstract][Full Text] [Related]
17. Status of the DPC4 tumor suppressor gene in sporadic colon adenocarcinoma of Croatian patients: identification of a novel somatic mutation.
Popović Hadzija M; Radosevic S; Kovacević D; Lukac J; Hadzija M; Spaventi R; Pavelić K; Kapitanović S
Mutat Res; 2004 Apr; 548(1-2):61-73. PubMed ID: 15063137
[TBL] [Abstract][Full Text] [Related]
18. Definition of a minimal region of deletion of chromosome 7 in uterine leiomyomas by tiling-path microarray CGH and mutation analysis of known genes in this region.
Vanharanta S; Wortham NC; Langford C; El-Bahrawy M; van der Spuy Z; Sjöberg J; Lehtonen R; Karhu A; Tomlinson IP; Aaltonen LA
Genes Chromosomes Cancer; 2007 May; 46(5):451-8. PubMed ID: 17285575
[TBL] [Abstract][Full Text] [Related]
19. Exomic landscape of MED12 mutation-negative and -positive uterine leiomyomas.
Mäkinen N; Vahteristo P; Bützow R; Sjöberg J; Aaltonen LA
Int J Cancer; 2014 Feb; 134(4):1008-12. PubMed ID: 23913526
[TBL] [Abstract][Full Text] [Related]
20. Allele-specific loss of heterozygosity at the DAL-1/4.1B (EPB41L3) tumor-suppressor gene locus in the absence of mutation.
Kittiniyom K; Mastronardi M; Roemer M; Wells WA; Greenberg ER; Titus-Ernstoff L; Newsham IF
Genes Chromosomes Cancer; 2004 Jul; 40(3):190-203. PubMed ID: 15138999
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
